Overview Dividends

(FDMT) 4D Molecular Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US35104E1001

Gene Therapy, Retinal Diseases, Cystic Fibrosis, Fabry Disease, Alpha-1

Biotechnology
Market Cap in USD: 418m
IPO / Inception: 2020-12-11
Return 12m vs S&P 500: 5.63%

EPS (Earnings per Share)

EPS (Earnings per Share) of FDMT over the last years for every Quarter: "2020-12": -2.36, "2021-03": -0.61, "2021-06": -0.28, "2021-09": -0.82, "2021-12": -0.85, "2022-03": -0.82, "2022-06": -0.87, "2022-09": -0.79, "2022-12": -0.84, "2023-03": -0.88, "2023-06": -0.77, "2023-09": -0.24, "2023-12": -0.75, "2024-03": -0.66, "2024-06": -0.63, "2024-09": -0.79, "2024-12": -0.9, "2025-03": -0.86, "2025-06": -0.98, "2025-09": -1.01, "2025-12": 0,
EPS CAGR: 45.03%
EPS Trend: 21.1%
Last SUE: 4.00
Qual. Beats: 1

Revenue

Revenue of FDMT over the last years for every Quarter: 2020-12: -0.977, 2021-03: 2, 2021-06: 14.58, 2021-09: 1.366, 2021-12: 0.092, 2022-03: 1.219, 2022-06: 0.162, 2022-09: 0.5, 2022-12: 1.247, 2023-03: 0.298, 2023-06: 0.239, 2023-09: 20.204, 2023-12: -0.019, 2024-03: 0.028, 2024-06: 0.005, 2024-09: 0.003, 2024-12: 0.001, 2025-03: 0.014, 2025-06: 0.015, 2025-09: 0.09, 2025-12: null,
Rev. CAGR: -0.58%
Rev. Trend: -24.2%
Last SUE: -0.08
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 94.5%
Value at Risk 5%th 134%
Relative Tail Risk -13.70%
Reward TTM
Sharpe Ratio 0.58
Alpha -5.37
CAGR/Max DD -0.32
Character TTM
Hurst Exponent 0.358
Beta 1.243
Beta Downside 1.453
Drawdowns 3y
Max DD 93.00%
Mean DD 51.94%
Median DD 54.19%

Description: FDMT 4D Molecular Therapeutics January 01, 2026

4D Molecular Therapeutics (NASDAQ: FDMT) is a late-stage biotech that leverages its proprietary Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors for ocular and systemic gene-therapy applications.

Its lead candidate, 4D-150, aims to treat retinal vascular diseases-including wet age-related macular degeneration (AMD) and diabetic macular edema-by delivering a single intravitreal injection that sustains anti-VEGF expression for multiple years, potentially displacing the current monthly anti-VEGF injection market, which is valued at > $8 billion globally.

Early-stage pipelines include 4D-710 for cystic fibrosis, 4D-175 for geographic atrophy, 4D-725 for α1-antitrypsin deficiency, and 4D-310 (Phase 1) for Fabry disease; the breadth of programs diversifies risk but also stretches cash resources.

Strategic collaborations with Astellas Gene Therapies, Arbor Biotechnologies, and uniQure provide both upfront licensing cash (≈ $30 M reported in 2024) and downstream development expertise, while the company’s cash runway of roughly 12 months (as of Q4 2025) underscores the importance of upcoming financing events.

Sector-wide, the AAV gene-therapy market is projected to grow at a CAGR of ~ 23 % through 2030, driven by regulatory incentives for rare-disease treatments and an aging population that expands the addressable pool for ocular indications.

For a deeper dive into FDMT’s valuation metrics and peer comparison, you might find the ValueRay platform useful.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-209.2m TTM) > 0 and > 6% of Revenue (6% = 7200 TTM)
FCFTA -0.44 (>2.0%) and ΔFCFTA -24.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 229.4k% (prev 2.83m%; Δ -2.60mpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.43 (>3.0%) and CFO -183.5m > Net Income -209.2m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 8.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (56.1m) change vs 12m ago 1.03% (target <= -2.0% for YES)
Gross Margin -80.7k% (prev -514.4k%; Δ 433.7kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.02% (prev 0.00%; Δ 0.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -13.38 (EBITDA TTM -226.8m / Interest Expense TTM -16.9m) >= 6 (WARN >= 3)

Altman Z'' -18.39

(A) 0.65 = (Total Current Assets 312.4m - Total Current Liabilities 37.1m) / Total Assets 424.0m
(B) -1.74 = Retained Earnings (Balance) -735.7m / Total Assets 424.0m
warn (B) unusual magnitude: -1.74 — check mapping/units
(C) -0.44 = EBIT TTM -226.1m / Avg Total Assets 514.0m
(D) -13.36 = Book Value of Equity -735.0m / Total Liabilities 55.0m
Total Rating: -18.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 34.23

1. Piotroski 0.0pt
2. FCF Yield data missing
3. FCF Margin data missing
4. Debt/Equity 0.06
5. Debt/Ebitda 0.12
6. ROIC - WACC (= -50.67)%
7. RoE -47.27%
8. Rev. Trend -24.20%
9. EPS Trend 21.09%

What is the price of FDMT shares?

As of January 09, 2026, the stock is trading at USD 7.30 with a total of 973,354 shares traded.
Over the past week, the price has changed by -0.27%, over one month by -34.12%, over three months by -24.43% and over the past year by +25.00%.

Is FDMT a buy, sell or hold?

4D Molecular Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy FDMT.
  • Strong Buy: 5
  • Buy: 4
  • Hold: 2
  • Sell: 0
  • Strong Sell: 1

What are the forecasts/targets for the FDMT price?

Issuer Target Up/Down from current
Wallstreet Target Price 33.1 353.6%
Analysts Target Price 33.1 353.6%
ValueRay Target Price 7 -4.4%

FDMT Fundamental Data Overview January 04, 2026

Market Cap USD = 418.2m (418.2m USD * 1.0 USD.USD)
P/S = 3485.2397
P/B = 1.1613
Beta = 2.948
Revenue TTM = 120.0k USD
EBIT TTM = -226.1m USD
EBITDA TTM = -226.8m USD
Long Term Debt = 22.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.70m USD (from shortTermDebt, last quarter)
Debt = 22.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -26.3m USD (from netDebt column, last quarter)
Enterprise Value = 135.4m USD (418.2m + Debt 22.3m - CCE 305.1m)
Interest Coverage Ratio = -13.38 (Ebit TTM -226.1m / Interest Expense TTM -16.9m)
FCF Yield = -136.6% (FCF TTM -185.1m / Enterprise Value 135.4m)
FCF Margin = -154.2k% (FCF TTM -185.1m / Revenue TTM 120.0k)
Net Margin = -174.3k% (Net Income TTM -209.2m / Revenue TTM 120.0k)
Gross Margin = -9999 % ((Revenue TTM 120.0k - Cost of Revenue TTM 97.0m) / Revenue TTM)
Gross Margin QoQ = -9999 % (prev -9999 %)
Tobins Q-Ratio = 0.32 (Enterprise Value 135.4m / Total Assets 424.0m)
Interest Expense / Debt = 6.34% (Interest Expense 1.41m / Debt 22.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -178.6m (EBIT -226.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.42 (Total Current Assets 312.4m / Total Current Liabilities 37.1m)
Debt / Equity = 0.06 (Debt 22.3m / totalStockholderEquity, last quarter 369.0m)
Debt / EBITDA = 0.12 (negative EBITDA) (Net Debt -26.3m / EBITDA -226.8m)
Debt / FCF = 0.14 (negative FCF - burning cash) (Net Debt -26.3m / FCF TTM -185.1m)
Total Stockholder Equity = 442.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -49.34% (Net Income -209.2m / Total Assets 424.0m)
RoE = -47.27% (Net Income TTM -209.2m / Total Stockholder Equity 442.6m)
RoCE = -48.64% (EBIT -226.1m / Capital Employed (Equity 442.6m + L.T.Debt 22.3m))
RoIC = -40.36% (negative operating profit) (NOPAT -178.6m / Invested Capital 442.6m)
WACC = 10.32% (E(418.2m)/V(440.5m) * Re(10.60%) + D(22.3m)/V(440.5m) * Rd(6.34%) * (1-Tc(0.21)))
Discount Rate = 10.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 29.90%
Fair Price DCF = unknown (Cash Flow -185.1m)
EPS Correlation: 21.09 | EPS CAGR: 45.03% | SUE: 4.0 | # QB: 1
Revenue Correlation: -24.20 | Revenue CAGR: -0.58% | SUE: -0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.93 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-3.48 | Chg30d=+0.000 | Revisions Net=+5 | Growth EPS=-6.8% | Growth Revenue=-40.2%

Additional Sources for FDMT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle